JEADV clinical practice最新文献

{"title":"Effectiveness of Carbon Dioxide Cryotherapy for the Treatment of Localized Cutaneous Leishmaniasis in Ethiopia","authors":"Feleke Tilahun Zewdu,&nbsp;Saba Maria Lambert,&nbsp;Michael Marks,&nbsp;Yematawork Kebede Aragaw,&nbsp;Derese Bekele Daba,&nbsp;Kassahun Alemu,&nbsp;Endalamaw Gadisa,&nbsp;Stephen L. Walker","doi":"10.1002/jvc2.70061","DOIUrl":"https://doi.org/10.1002/jvc2.70061","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Cutaneous leishmaniasis (CL) is a public health problem in Ethiopia. Diagnosis is often delayed, and treatment options are limited. Liquid nitrogen cryotherapy is a recommended treatment but not widely available. Carbon dioxide (CO₂) cryotherapy is used for the prevention of cervical cancer and is widely available in Ethiopia and might be a suitable therapy for treating localized CL.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>The aim of this short report is to assess the effectiveness of carbon dioxide cryotherapy for the treatment of CL in CL treatment centre, Ethiopia.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We performed a prospective study assessing the effectiveness of CO₂ cryotherapy for the treatment of localized CL between September 2022 and June 2023 at an established CL treatment centre.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Seventeen individuals with 24 CL lesions were enrolled. Twelve (70.6%) were confirmed using a skin slit smear and five by histopathology (29.4%). Nine (52.9%) individuals received a single session of CO₂ cryotherapy, five received two (29.4%) and three (17.65%) received three sessions of cryotherapy. At Day 90, 16 participants were assessed and 14 (82.4%) had healed.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>CO₂ cryotherapy shows promise as a potential treatment strategy for CL. Formal evaluations are required.</p>\u0000 </section>\u0000 </div>","PeriodicalId":94325,"journal":{"name":"JEADV clinical practice","volume":"4 4","pages":"830-835"},"PeriodicalIF":0.5,"publicationDate":"2025-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jvc2.70061","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144923707","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patient and Clinician-Reported Outcomes and Adherence to Calcipotriene/Betamethasone Dipropionate PAD-Cream in Treatment of Scalp Psoriasis in Adults: An Interim Analysis of the PRO-SCALP Study","authors":"Andreas Pinter,&nbsp;Jose Luis López Estebaranz,&nbsp;Anthony Bewley,&nbsp;Jordi Galván,&nbsp;Siva Narayanan,&nbsp;Volker Koscielny,&nbsp;Ismail Kasujee","doi":"10.1002/jvc2.70058","DOIUrl":"https://doi.org/10.1002/jvc2.70058","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Effective management of scalp psoriasis needs treatment with high patient preference and treatment satisfaction. Clinical trials show promising results for calcipotriene and betamethasone dipropionate cream based on polyaphron dispersion (PAD) technology (CAL/BDP PAD-cream). However, real-world data are scarce.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>To evaluate patient- and clinician-reported outcomes and impact of adherence on treatment outcomes of CAL/BDP PAD-cream in adults with mild-to-moderate scalp psoriasis in real-world settings in Europe.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>PRO-SCALP is an ongoing observational, multicentre cohort study, collecting data primarily at baseline and Week 8 (end of the study, EOS). Patient self-assessments included Treatment Satisfaction Questionnaire for Medication Version 9 (TSQM-9), Scalpdex questionnaire, Worst Itch-Numerical Rating Scale (WI-NRS), sleep patterns, personal preferences and adherence to CAL/BDP PAD-cream using a visual analogue scale (VAS). Clinicians' assessments included physician global assessment of scalp (scalp-PGA) and S-mPASI.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Of 152 patients included in this interim analysis, 134 patients (mean age: 48.4 years; 69.4% females) had evaluable outcome data. At EOS, mean (SD) patient satisfaction scores (TSQM-9) were—effectiveness: 76.0 (23.9), convenience of use: 70.2 (21.3), global satisfaction: 76.1 (22.5). At Week 8, 79.0% of patients attained a scalp-PGA score of 0 (clear) or 1 (almost clear), and 71.0% attained scalp-PGA success, defined as a scalp PGA score of 0/1 and ≥ 2-points improvement in scalp-PGA score change from baseline (CFB). CFB of S-mPASI scores, patient-reported symptoms, emotions, functioning and overall Scalpdex scores as well as WI-NRS scores improved significantly (<i>p</i> &lt; 0.0001) at EOS, within both low-adherence (VAS &lt; 80) and high-adherence (VAS: 80−100) groups. Across key outcome measures, CFB of treatment outcomes was found to be better in patients with higher adherence.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Findings of the study indicate high treatment satisfaction, significant improvement in clinical outcomes and patients' quality of life associated with CAL/BDP PAD-cream, especially in patients with higher adherence.</p>\u0000 </section>\u0000 </div>","PeriodicalId":94325,"journal":{"name":"JEADV clinical practice","volume":"4 4","pages":"791-802"},"PeriodicalIF":0.5,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jvc2.70058","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144923662","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Synchronous Melanoma: A Single-Centre 5-Year Retrospective Study","authors":"Ji Fung Yong,&nbsp;Michael O'Connell,&nbsp;Alana Durack,&nbsp;Lyndsey Paul","doi":"10.1002/jvc2.70064","DOIUrl":"https://doi.org/10.1002/jvc2.70064","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Synchronous melanoma (SM) is defined as ≥ 2 melanomas diagnosed at the same time, or within 3 months of diagnosing the first melanoma, and occurs rarely.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>The objective of this study was to review all the cases of SM discussed at the melanoma MDT meeting in our cancer centre over the last 5 years.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Melanoma MDT lists, histopathology and clinical records were reviewed from July 2018 to July 2023 inclusive, for new SMs. This study includes invasive malignant melanoma (MM), lentigo maligna (LM) and melanoma in situ (MIS).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>1082 patients were diagnosed with cutaneous melanomas over the 5-year period. Of these patients, 33 patients (3.05%) with SMs were identified in 21 males and 12 females. Ages ranged from 44 to 93 years. Twenty-four patients (72.7%) had SMs diagnosed at the same time and nine (27.3%) had subsequent melanoma diagnosed within a 3-month period. Risk factors noted included family history of melanoma (6.06%, <i>n</i> = 2), history of immunosuppression (12.1%, <i>n</i> = 4), and history of previous non-melanoma skin cancer (6.06%, <i>n</i> = 2). Of the total number of SMs (<i>n</i> = 68), 26.5% (<i>n</i> = 18) were invasive, 20.6% (<i>n</i> = 14) were LMs and 52.9% (<i>n</i> = 36) were MIS. Most lesions (33.9%, <i>n</i> = 21) were located on the trunk, with 13 (62%) on the back. Sixteen (48.5%) patients had both synchronous in situ lesions, 16 patients had LM/MIS with an invasive melanoma (pathological stage 1a to 4b) and 1 (2.4%) patient had stage 1a with stage 1b melanoma.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>To the best of our knowledge, this is the largest retrospective study to date of SM. It highlights the importance of a full skin check especially once a melanoma has been identified, to ensure further melanomas are not missed.</p>\u0000 </section>\u0000 </div>","PeriodicalId":94325,"journal":{"name":"JEADV clinical practice","volume":"4 4","pages":"840-844"},"PeriodicalIF":0.5,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jvc2.70064","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144923660","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mycosis Fungoides in Paediatric Patients: A Real-Life Retrospective Study","authors":"Mariana de la Vega,&nbsp;María Antonieta Domínguez Gómez,&nbsp;Martha Alejandra Morales-Sánchez","doi":"10.1002/jvc2.70059","DOIUrl":"https://doi.org/10.1002/jvc2.70059","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Mycosis fungoides (MF) is the most common type of cutaneous T cell lymphoma, and less than 5% of cases occur in paediatric patients. No treatment standardized guidelines exist for paediatric population, and evidence comes from small retrospective studies. No studies in Mexican children were identified.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>To describe epidemiological data, to determine treatment response and factors associated with remission or relapse, and to examine the impact of diagnosis delay in complete remission.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We retrospectively analysed records of all patients aged 0−18 years diagnosed with MF who were treated in Centro Dermatológico Pascua, between January 2007 and July 2023.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>One hundred and twenty-three patients were included. The median age at diagnosis was 12 years. All patients presented with early clinical stages (IA/IB). Hypopigmented phenotype was present in 70.7%. Phototherapy was the most frequently indicated treatment (89.4%). Complete remission was achieved by 35.8% in a median of 16.54 ± 14.74 months. Involved body surface area (BSA), duration of disease and phototherapy were inversely associated with complete remission. The median time to follow-up was 19 months (range 40 months), with an overall survival of 100%, and no disease progression. Relapse was present in 15.44%, and associated predictors were skin phototype and clinical variants different from hypopigmented. BSA and the duration of the disease were negatively associated. Institutional diagnosis delay had a median of 3 months (range 0.8−10.7 months), with no statistically significant impact in complete remission.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>To our knowledge, this study represents the largest paediatric cohort worldwide, and the first to examine the Mexican population. Phototherapy is the most prescribed treatment modality in our centre, with acceptable remission rates. Our study confirms a favourable prognosis of MF in children. Prospective studies are needed to better characterize the epidemiology and clinical course of the disease, to determine treatment efficacy and to identify prognostic factors.</p>\u0000 </section>\u0000 </div>","PeriodicalId":94325,"journal":{"name":"JEADV clinical practice","volume":"4 4","pages":"783-790"},"PeriodicalIF":0.5,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jvc2.70059","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144923659","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genital Psoriasis: Shining Light on This Hidden Disease","authors":"Jennifer Cather,&nbsp;Melodie Young,&nbsp;Muriel Boreham,&nbsp;Shehla Admani,&nbsp;Tina Bhutani,&nbsp;Erin Foster,&nbsp;Richard Fried,&nbsp;Melinda Gooderham,&nbsp;Jeannette Jakus,&nbsp;Sandra Johnson,&nbsp;Ryoichi Kamide,&nbsp;John Koo,&nbsp;Tiffany Mayo,&nbsp;Michael Payette,&nbsp;Caitriona Ryan,&nbsp;Lucinda Whitney,&nbsp;Krista Bohnert,&nbsp;Melissa Seal,&nbsp;Patrick Burnett,&nbsp;Diane Hanna","doi":"10.1002/jvc2.70043","DOIUrl":"https://doi.org/10.1002/jvc2.70043","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Psoriasis occurring on the skin of the genital and perigenital regions, including the inguinal creases, vulva, penis, scrotum, perianal area, and the intergluteal cleft, has specific diagnostic and treatment requirements due to the sensitivity and private nature of these areas.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>A multidisciplinary group of 13 US-based clinicians who are experts in the management of genital psoriasis, the Genital Psoriasis Wellness Consortium, convened to discuss the impact of genital psoriasis on patients focusing on three main domains: (1) physical diagnosis and patient conversations, (2) impact on patient quality of life/interpersonal relationships, and (3) treatment decisions.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A PubMed literature search was conducted, and the Consortium members used the results to formulate their consensus statements using a modified Delphi process, including a nominal group technique. The process included two rounds of virtual subcommittee meetings based on the three domains, followed by surveys to obtain anonymous feedback, and concluded with a final meeting to discuss and finalize the language of the consensus recommendations across all three domains. Three additional psoriasis experts provided feedback on these consensus statements from Canadian, European, and Asian perspectives.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Herein, we report our 14 consensus statements and a summary of the supporting data.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>These consensus statements are meant as a practical resource for clinicians to ensure that symptoms of genital psoriasis are not overlooked. We hope to continue to add to these statements as additional clinical data become available.</p>\u0000 </section>\u0000 </div>","PeriodicalId":94325,"journal":{"name":"JEADV clinical practice","volume":"4 4","pages":"719-731"},"PeriodicalIF":0.5,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jvc2.70043","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144923661","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of Psychiatric Comorbidities With Chronic Urticaria: A Nested Case-Control Study in the All of Us Research Program","authors":"Nana A. Adjei-Frimpong,&nbsp;Julian Cortes,&nbsp;Savannah K. Fakhouri,&nbsp;Francesco Delacqua,&nbsp;Reid Oldenburg","doi":"10.1002/jvc2.70063","DOIUrl":"https://doi.org/10.1002/jvc2.70063","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Chronic urticaria (CU) is characterised by recurring itchy hives lasting more than 6 weeks, with or without angioedema. Although CU patients are known to have an increased likelihood of psychiatric comorbidities, research exploring this connection in diverse populations remains limited.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>This study investigates the association between CU and psychiatric disorders using the All of Us (AoU) database, a nationwide initiative designed to enhance research in underrepresented populations.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We conducted a nested case-control study among US adults in the AoU program from May 6, 2018 to February 26, 2025. SNOMED codes were used to identify CU cases that were then matched 4:1 to controls by age, sex, ethnicity, and smoking status. Psychiatric comorbidities were assessed using logistic regression models adjusted for hypothyroidism, systemic lupus erythematosus, and rheumatoid arthritis.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>We identified 1171 CU cases and 4684 matched controls. CU was significantly associated with increased odds of ADHD (odds ratio [OR], 3.61; 95% confidence interval [CI], 2.62–4.96), anxiety (OR, 3.48; 95% CI, 3.03–3.99), depression (OR, 3.26; 95% CI, 2.84–3.75), dysthymia (OR, 3.67; 95% CI, 2.89–4.66), insomnia (OR, 3.27; 95% CI, 2.77–3.86), psychological stress (OR, 3.92; 95% CI, 3.09–4.96), PTSD (OR, 3.25; 95% CI, 2.53–4.17), and substance use disorder (OR, 2.13; 95% CI, 1.74–2.62).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>These findings highlight the psychiatric burden associated with CU and demonstrates the importance of routine psychiatric screenings for CU patients to allow early intervention. Prospective studies investigating additional psychiatric disorders and underlying mechanisms will help clarify meaningful associations and guide appropriate psychiatric screening and management.</p>\u0000 </section>\u0000 </div>","PeriodicalId":94325,"journal":{"name":"JEADV clinical practice","volume":"4 4","pages":"836-839"},"PeriodicalIF":0.5,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jvc2.70063","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144923637","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Association of Psoriasis With Sleep Disorders in a Diverse National Cohort","authors":"Michael J. Diaz,&nbsp;Zaim Haq,&nbsp;Jasmine T. Tran,&nbsp;Parsa Abdi,&nbsp;Nicole Natarelli,&nbsp;Wilson Liao,&nbsp;Marjorie E. Montanez-Wiscovich","doi":"10.1002/jvc2.70022","DOIUrl":"https://doi.org/10.1002/jvc2.70022","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Higher prevalence of sleep disorders is seen in persons with psoriasis (PsO). However, the extent to which sleep conditions are linked to PsO severity, particularly across diverse populations, remains unknown. Bridging this knowledge gap is vital for developing comprehensive, equitable and personalized care strategies.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>We aimed to quantify the extent to which psoriasis severity correlates with the risk of developing specific sleep disorders, and to identify how these associations vary by racial/ethnic group, using robust covariate adjustments.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Health records for 7743 adults with psoriasis were obtained from the All of Us sample—an NIH database initiative that oversamples underrepresented populations. Cases were selectively matched 1:4 to age-, sex-, and race/ethnicity-matched controls, and differences were interrogated by multivariable regression.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Mild PsO was significantly associated with restless leg syndrome, insomnia and obstructive sleep apnoea after adjusting for sociodemographic variables and comorbidities. Moderate-to-severe PsO demonstrated greater magnitudes of association. We additionally observed a magnified sleep disorder risk in non-White patients, particularly for insomnia and OSA.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Both mild and moderate-to-severe psoriasis is significantly associated with an increased risk of sleep disorders, with notable variations across different racial/ethnic groups.</p>\u0000 </section>\u0000 </div>","PeriodicalId":94325,"journal":{"name":"JEADV clinical practice","volume":"4 4","pages":"821-825"},"PeriodicalIF":0.5,"publicationDate":"2025-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jvc2.70022","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144923726","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment Survival in Patients With Hidradenitis Suppurativa","authors":"Lea Schulte-Oestrich,&nbsp;Simone Cazzaniga,&nbsp;Robert E. Hunger,&nbsp;S. Morteza Seyed Jafari","doi":"10.1002/jvc2.70027","DOIUrl":"https://doi.org/10.1002/jvc2.70027","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Despite the existence of therapeutic approaches, effective management of hidradenitis suppurativa (HS) remains elusive in many cases. In addition, most of the current studies focus on treatment response in a cross-sectional analysis of patients, and therefore a proper study analysing different treatment strategies longitudinally in each individual patient is still lacking.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>The current study aimed to provide insight into HS patients treated with different treatment strategies and to clarify the reasons for switching or discontinuing each treatment group.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>The single-center, retrospective study collected information on patient characteristics and management strategies, focusing on different treatment groups and reasons for discontinuation or switching.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Ninety-eight patients were included in the study (53.1% males, median age 38.5 years). During the study period, 98.0% of patients had at least one prescription of topical therapy, particularly non-antibiotics disinfectants. 92.9% of patients also received a prescription for systemic antibiotics, especially tetracyclines (86.7%). 26.5% were prescribed biologic therapies, mainly TNF-alpha blockers (25.5%), with a median time to start treatment of 0.9 years. Non-biologic systemic therapies (relative risk [RR]: 1.54; 95% confidence interval [CI] 1.28–1.85) and systemic antibiotics (RR: 1.97; 95% CI: 1.56–2.48) showed a moderate-to-high risk of discontinuation. The most frequent switching patterns were from topicals plus systemic antibiotics to the same combination plus other therapies (11.2%), including surgery and laser, to topical treatment alone (8.5%), or to topicals plus biologics (4.5%).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Standard care management of HS requires a personalized, multifaceted approach, typically involving a combination of local and systemic treatments, with antibiotics often used first. When antibiotics and other systemic agents are ineffective, biologics may be used alone or with antibiotics; delaying their use can miss the chance to prevent disease progression and the possible ‘window of opportunity’ in the treatment of HS.</p>\u0000 </section>\u0000 </div>","PeriodicalId":94325,"journal":{"name":"JEADV clinical practice","volume":"4 4","pages":"751-758"},"PeriodicalIF":0.5,"publicationDate":"2025-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jvc2.70027","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144923435","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Defining Core Concepts for Health-Related Quality of Life for Patients With Mycosis Fungoides and Sézary Syndrome: A Systematic Literature Review","authors":"Christina Asare,&nbsp;Jennifer Chen,&nbsp;Pragna Naidoo,&nbsp;Caroline Raymundo,&nbsp;Marianne Tawa,&nbsp;Nilufer Khan,&nbsp;Elise Olsen,&nbsp;Rosanne Ottevanger,&nbsp;Julia Scarisbrick,&nbsp;Susan Thornton,&nbsp;Ellen J. Kim,&nbsp;Cecilia Larocca,&nbsp;Michi M. Shinohara,&nbsp;International Dermatology Outcomes Measures (IDEOM) CTCL Workgroup","doi":"10.1002/jvc2.70039","DOIUrl":"https://doi.org/10.1002/jvc2.70039","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>There is no consensus on how best to assess the impact of living with mycosis fungoides (MF)/Sézary syndrome (SS) on a patient's quality of life.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>To identify all potential concepts that describe disease severity or contribute to health-related quality of life (HRQOL) from patients with MF/SS and their care partners.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A systemic literature review of articles and meeting abstracts published between 2000 and 2022 was conducted. Inclusion criteria were any study that included MF/SS patients or care partners and reported any concept that patients or care partners could use to characterize any aspect of MF/SS. Thematic analysis was completed using NVIVO.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>One hundred and three articles/abstracts met inclusion criteria. Within these studies, 30 existing instruments were utilized. Concepts within these existing instruments fell into the following health component categories: Physical-functional well-being (PF; 50.4%), mental health/emotional well-being (MHE; 26.6%), social well-being (S; 18.3%) or other (O; 4.7%). The most frequently measured concepts by existing instruments were physical mobility (7.5%), itching (7.2%), pain (7.0%) and fatigue (5.2%). One study conducted content validity analysis for an included instrument. Distinct concepts were identified from qualitative studies and novel instruments, and included hair loss, nail changes, cracking/fissuring of the skin, inability to regulate temperature, difficulty with wound dressings, skin infection, skin oozing/weeping/bleeding, pigmentary changes, treatment burden and treatment satisfaction, and care partners' specific concepts. One study conducted content validity analysis for an included instrument.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Numerous PROMs have been used to assess HRQOL for patients with MF/SS, with very little content validity analysis. Several concepts identified from qualitative studies and newly developed or piloted instruments are not represented in existing PROMs. Future efforts will include prioritizing candidate core concepts by stakeholders to develop a core domain set that captures the most relevant aspects of MF/SS that impact HRQOL.</p>\u0000 </section>\u0000 </div>","PeriodicalId":94325,"journal":{"name":"JEADV clinical practice","volume":"4 4","pages":"907-919"},"PeriodicalIF":0.5,"publicationDate":"2025-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jvc2.70039","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144923439","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Targeting JAK-1 in Disseminated Cutaneous Lichen Planus","authors":"F. Barbosa,&nbsp;L. Siems,&nbsp;D. Luz,&nbsp;A. Duarte","doi":"10.1002/jvc2.70054","DOIUrl":"https://doi.org/10.1002/jvc2.70054","url":null,"abstract":"<p>We report the case of a 63-year-old woman with an exuberant and recalcitrant clinical presentation of LP who had an excellent response to 200 mg/day abrocitinib, a JAK-1 inhibitor, after failure to other commonly used therapies. The efficacy of JAK inhibitors in lichen planus is supported by small case series and isolated case reports. Further studies are necessary to confirm their full potential.</p>","PeriodicalId":94325,"journal":{"name":"JEADV clinical practice","volume":"4 4","pages":"880-882"},"PeriodicalIF":0.5,"publicationDate":"2025-05-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jvc2.70054","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144923611","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}